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Click and learn: new-look 
best practice portal
Real-life responses to drug problems 
came under the spotlight in October as 
the EMCDDA launched its revamped 
Best practice portal (1). Targeted at 
practitioners and professionals working 
in the drugs field, the portal is designed 
as a practical and reliable source of 
what works, and what doesn’t, in the 
areas of drug-related prevention, 
treatment, harm reduction and social 
reintegration.
The new-look portal helps users identify 
tried and tested interventions quickly; 
allocate resources to what’s effective; 
evaluate and improve interventions, by 
applying practical tools, standards and 
guidelines; and take better decisions, 
gaining from experience and expertise 
across Europe. Aiming to ‘put the user 
first’, the portal is the result of an 
extensive process of user-testing. 
Among its revised features are a dynamic 
FAQ section, to which users can add 
their own questions, as well as a raft of 
new search functions.
Summarising evidence in plain language, 
demystifying terminology and answering 
real questions from the field, the 
re-designed portal provides an 
accessible tool to support the 
development of evidence-based 
interventions. Using an information-
layering approach, a vast array of data 
and research is presented in top-level 
‘answer sheets’, complemented by 
underlying levels demonstrating the 
current evidence base.
Among the portal’s added value is its 
overview of standards and guidelines 
available in the EU Member States to 
boost the quality of interventions. 
This comes at a time when Europe’s 
health and social responses to drug 
problems are increasingly supported by 
guidelines and quality standards, which 
translate evidence into satisfactory and 
sustainable results (see p. 3).
The portal concentrates on illicit drugs 
and polydrug use and has a clear 
European focus. Intended as a ‘living 
product’, it will be regularly updated as 
information and research on interventions 
emerge. The main body of the portal is in 
English, but documents in other EU 
languages are also available according to 
where the interventions occur.
 Marica Ferri and Alessandra Bo 
(1) For more, see www.emcdda.europa.eu/
best-practice
The new-look portal offers a raft of new search 
functions.
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EMCDDA scientific paper award 2014
The four winners of the 2014 EMCDDA 
scientific paper award were honoured in 
Lisbon on 25 November at the annual 
ceremony hosted by the agency (1). 
The winners received a non-monetary 
prize for their articles at an event held in 
the margins of the third ‘Reitox week’ 
(see p. 6).
The prize, inaugurated in 2011 by the 
EMCDDA and its Scientific Committee, 
celebrates scientific writing and 
distinguishes high-quality research in the 
field of illicit drugs. This year, a record 
number of papers was nominated by 
members of the EMCDDA Scientific 
Committee, the Reitox focal points, 
scientific journals and EMCDDA staff. 
Over 60 eligible articles authored by 
European scientists and published in 
peer-reviewed journals in 2013 were 
assessed by an award committee. 
The winners (primary authors) are: 
Florian Buchmayer (Austria; represented 
by Harald Sitte); Annabeth Groenman 
(Netherlands); Michael P. Schaub (for a 
paper written in the framework of EQUS, 
an EC-funded project) and Jürgen Rehm 
(Germany). See page 8 for further 
details.
 Maria Moreira and Renate Hochwieser 
(1) www.emcdda.europa.eu/activities/scientific-
paper-award
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KEY INDICATORS
High-risk drug use and treatment
‘Continuity and change: high-risk drug use and drug treatment 
in Europe’, was the focus of a series of events held at the 
EMCDDA from 23–26 September (1). Two parallel expert 
meetings, dedicated to the agency’s treatment demand key 
indicator (TDI) and the problem drug use indicator (PDU), 
preceded a broader, common event open to specialists from 
outside the two groups.
The initiative was in line with a fresh, integrated approach to the 
agency’s expert meetings, designed to inspire cross-discipline 
analyses of the drugs problem and responses to it. Through this 
approach, the EMCDDA intends to obtain greater value from 
these annual events, strengthening what have become, over the 
last 10 years, valuable networks of excellence.
While the two key indicator meetings explored important 
technical issues related to the implementation of these tools, the 
conference-style meeting focused on data- and multi-indicator 
analyses and monitoring drug treatment (as an epidemiological 
data source and a response to the drugs problem). Issues 
debated included: trends and developments in high-risk opioid 
use; ageing drug users; vulnerable populations; high-risk use of 
stimulants, benzodiazepines and cannabis; treatment outcomes; 
and evaluating best practice.
The results of an online evaluation survey are now being 
examined in an effort to improve future events. The conclusions 
of the meeting, along with presentations and abstracts, will be 
available in the coming weeks (2).
 Expert meeting organising team 
(1) www.emcdda.europa.eu/news/2014/fs10
(2) www.emcdda.europa.eu/activities/expert-meetings/2014/ki-event
ADDICTIONS
Lisbon Addictions 2015
The organisers of the first European conference on addictive 
behaviours and dependencies — to be held in Lisbon from 
23–25 September 2015 — launched a call for abstracts on 
31 October with a deadline of 1 March 2015 (1). The event is 
steered by the Portuguese General-Directorate for Intervention 
on Addictive Behaviours and Dependencies (SICAD), in 
collaboration with the scientific journal Addiction, the 
International Society of Addiction Journal Editors (ISAJE) and 
the EMCDDA.
Through plenary sessions, multidisciplinary workshops and 
discussion fora, the conference will showcase the latest 
developments in European addiction science and explore the 
topics of illicit drugs, alcohol, tobacco, gambling and other 
addictive behaviours. It will draw on expertise from a variety of 
disciplines including: epidemiology, policy and clinical research, 
social sciences and human psychopharmacology.
The event is organised around four general themes: Addictions: 
a multi-disciplinary perspective; Translating research into policy 
and practice; New frontiers in addiction research; and 
Challenges of addiction in an interconnected world.
The conference will provide a unique networking opportunity for 
researchers, practitioners and policy experts across countries 
and disciplines and address new challenges and developing 
fields. Abstracts are invited for papers, rapid communications 
and symposia. Online registration will open in December 2014, 
with an ‘early-bird’ fee available for participants registering 
before 1 February 2015.
 Maria Moreira, Renate Hochwieser and Alberto Oteo 
(1) www.lisbonaddictions.eu | info@lisbonaddictions.eu
KEY INDICATORS
Drug-related harms and responses
Latest evidence in the area of drug overdose and HCV and HIV 
infections among drug users were among the topics discussed 
during a week of events organised by the EMCDDA from 15–17 
October. Two EMCDDA expert meetings, dedicated to the 
agency’s drug-related deaths and mortality key indicator (DRD) 
and the drug-related infectious diseases key indicator (DRID) 
were preceded by a satellite event focusing on the role of 
take-home naloxone in reducing opioid-related fatalities.
Epidemiologists, clinicians, public health practitioners and 
representatives of civil society brought their multifaceted 
expertise to the table and shared perspectives with the Reitox 
national focal points and international organisations. Among 
the issues highlighted was Europe’s HCV epidemic among 
people who inject drugs and the need for scaling up treatment. 
Treatment coverage for HCV is very low in Europe, compared to 
levels stipulated in current guidelines. Yet, there exists the 
potential to tackle the 
problem: effective HCV 
treatments have been 
available for some years and 
new treatments are being 
released (1). These, together 
with harm reduction 
measures, can contribute to 
the prevention of new 
infections and help control 
the epidemic. 
Also raised at the meetings 
were: the resurge in heroin-related deaths in some European 
countries and new HIV infections related to the injection of 
stimulants. Documentation from the meetings is now available (2).
 Expert meeting organising team 
(1) www.emcdda.europa.eu/topics/pods/hepatitis-c-treatment
(2) www.emcdda.europa.eu/expert-meetings/2014/drd-drid 
www.emcdda.europa.eu/events/2014/meetings/naloxone
HCV: new treatments being released.
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BEST PRACTICE
From guidelines to quality 
standards
The promotion and exchange of best practice is recognised 
globally as an important strategy to improve the effectiveness 
of drug-related interventions and ensure the efficient use of 
limited resources. Currently, the most common strategy in 
Europe to promote best practice is the development of 
guidelines. However, a strong interest in quality standards — 
used to implement the interventions recommended in 
guidelines — also appears to be emerging in the quest for 
quality in drug services. 
This development is not only noticeable at national level, but 
also at regional and international level (1). For example, the 
African Union’s plan of action on drug control (2013–17) and the 
Hemispheric drug strategy and action plan of the Organisation 
of American States (2011–15) both invite member countries to 
develop and adopt qualitative standards. UNODC is also active 
in this field: it adopted international prevention standards in 
2013 and is now working towards treatment standards (2). 
In Europe, a number of noteworthy projects have generated 
important knowledge in the scientific field (3). At a political level, 
the EU is calling on its Member States, before the end of 2016, 
to agree on, adopt and start implementing, minimum quality 
standards in drug use prevention, treatment, risk and harm 
reduction, rehabilitation and recovery (4).
Evidence-based quality mechanisms, ensuring effective drug 
services, are still not the norm in Europe or worldwide. This new 
trend in setting quality standards has the potential to boost the 
promotion of effective drug-related interventions.
 Marica Ferri, Danilo Ballotta and Alessandra Bo 
(1) www.emcdda.europa.eu/publications/emcdda-papers/regional-drug-
strategies
(2) www.unodc.org/unodc/en/prevention/prevention-standards.html
(3) Schaub and Uchtenhagen, 2013; and Sumnall and Brotherhood, 2011.
(4) Action 9, EU action plan on drugs (2013–16).
RESPONSES
ACADEMIA
European drugs summer school
For the fourth year in a row, 
the University Institute of 
Lisbon (ISCTE–IUL) and the 
EMCDDA will be joining 
forces in July 2015 to hold 
the European summer 
school on ‘Illicit drugs in 
Europe: demand, supply and 
public policies’ (1). 
The decision follows positive feedback from the 2014 students 
via a course evaluation questionnaire.
The first three summer schools brought together close to 100 
students from Europe, Asia, Latin America and the US. 
Scholarships were available from ISCTE–IUL and from the 
international programme of the US National Institute on Drug 
Abuse (NIDA). 
Adopting a multidisciplinary and interactive approach, the 
two-week course aims to prepare participants to meet today’s 
complex policy challenges in the drugs field. Trainers will 
include EMCDDA scientific experts, policymakers and ISCTE 
professors. A new line of ‘keynote speakers’ will be announced 
early next year. 
The course is open to university students (undergraduate, 
graduate and postgraduate), researchers, professionals and 
administrators interested, or working, in the drugs field. 
In 2015, participants will be able to take advantage of 
‘early-bird’ reductions.
 Renate Hochwieser and Marica Ferri 
(1) For more, see www.drugsummerschool.cies.iscte-iul.pt
OVERDOSE PREVENTION
Take-home naloxone: review
The role of take-home naloxone (THN) in reducing opioid-
related fatalities has been the focus of recent events and 
studies at the EMCDDA (1). Naloxone is an opioid antagonist 
used in emergency medicine worldwide as an effective antidote 
to opioid intoxication (including intoxication by synthetic 
opioids). As many overdoses occur in the presence of peers or 
family members, programmes that enable bystanders to 
provide First Aid and administer naloxone while awaiting 
emergency services, can save lives.
In 2013–14, the EMCDDA carried out a systematic review of the 
literature to analyse the available evidence supporting THN 
provision to reduce opioid overdose fatalities (2). The review 
identified and analysed 21 studies of varying design-types, 
conducted in several countries (Canada, Germany, UK, US). 
The overall results suggest that educational and training 
interventions using naloxone provision may be effective in 
decreasing overdose-related mortality and improving 
knowledge around the signs of overdose and the correct 
management of patients.
Entitled Effectiveness of take-home emergency naloxone to 
prevent heroin overdose, the review was presented at an 
EMCDDA naloxone event in October and will be published as an 
EMCDDA Paper in the coming months (3).
 Marica Ferri and Lucas Wiessing 
(1) For more, see www.emcdda.europa.eu/topics/pods/preventing-overdose-
deaths
(2) Undertaken with the Cochrane drugs and alcohol group.
(3) For more, see www.emcdda.europa.eu/events/2014/meetings/naloxone 
EMCDDA Papers are available at www.emcdda.europa.eu/publications/
emcdda-papers
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BOOKSHELF FEATURE
Marijuana 
legalization
Marijuana (herbal cannabis) is 
controlled by the international drug 
treaties and by national and local laws 
across the globe. But those laws are 
now being challenged in several 
countries. In the US, while there is no 
short-term prospect for changes to 
federal law, some 20 states now allow 
medical use of the drug and, in recent 
years, initiatives to legalise production 
and non-medical use have gained 
support.
These are among the issues explored 
in Marijuana Legalization: What 
Everyone Needs to Know. The book 
aims to provide readers with a 
non-partisan briefing on this topic, 
covering everything from the risks and 
benefits of using the drug, to 
describing the current laws around it, 
both in the US and elsewhere. 
The authors discuss the likely costs 
and benefits of legalisation at state 
and national levels and consider how 
marijuana legalisation could personally 
impact heavy users, medical users, 
parents, drug traffickers and 
employers.
Authors: Jonathan P. Caulkins, Angela 
Hawken, Beau Kilmer and Mark 
Kleiman
Publisher: Oxford University Press
Languages: English
Date: July 2012
ISBN: 978-01-9-991373-2
Further details: http://global.oup.com
The EMCDDA is responsible for the selection of 
materials for the Bookshelf and for the text 
presented. However, responsibility for the content 
of these materials and the opinions expressed 
therein lies with the authors themselves.
Financing drug policy in Europe in the wake of 
the economic recession
In 2008, and the years that followed, 
Europe experienced a severe economic 
crisis, which presented a grave challenge 
to the public purse. Many governments 
reacted by implementing stringent fiscal 
consolidation plans, frequently based on 
the reduction of government spending.
A new EMCDDA Paper explores how the 
economic recession has affected the 
financing of drug initiatives in Europe (1). 
It focuses broadly on the financing of areas 
where most drug-related initiatives are 
concentrated (i.e. public order and safety; 
health and social protection) as well as specifically on drug-related public expenditure.
The report concludes that:
n  austerity differed considerably across countries in Europe (2); 
n  austerity led to reductions in spending in the areas of government activity that 
finance drug initiatives in Europe, on average, in 2011;
n  countries experiencing greater levels of austerity tended to show greater 
reductions in expenditure;
n  larger cuts were registered in expenditure on health than on public safety and 
social protection.
Available estimates of drug-related public expenditure do not reveal the full picture on 
the impact of the recession. However, they suggest that, with the recession, drug 
budgets were more likely to be revised (often resulting in cuts); that the impact of 
austerity on drug policy was more severe in the countries hardest hit by the economic 
crisis; and that some sectors were more affected than others.
The financing of drug prevention initiatives was particularly hit, leading to the 
downsizing of prevention programmes and to a greater awareness of the need for 
more quality-control and evidence-based funding. Different outcomes were reported 
for drug treatment and harm reduction programmes. Some countries opted for: the 
reorganisation of these services; changes in co-financing systems; a shift towards 
outpatient treatment or day-care treatment over inpatient drug treatment; and 
attempts to increase the cost-effectiveness of health provision via reorganisation. 
Furthermore, among the small number of countries providing estimates for their 
spending on supply reduction, all but one reported either short-term or lasting 
reductions in funding. All in all, the report shows how austerity raised policymakers’ 
awareness of the need for cost-effective policy measures, leading to attempts to 
reorganise drug services in some countries.
The potential negative impact of the 2008 recession has been stressed by the 
international community. In 2014, the UN Commission on Narcotic Drugs agreed on a 
joint resolution highlighting the need to provide sufficient health services to 
individuals affected by substance disorders and encouraging countries to ensure that, 
during economic downturns, national drug policies are not disproportionately affected. 
This latest EMCDDA Paper provides important insights into the likely impact of the 
recession on the financing of drug policy in Europe, presenting unique information and 
data. But it also raises awareness of the need to improve data availability in this area 
to allow for improved analyses and evidence-based responses.
 Cláudia Costa Storti 
(1) Available in English at www.emcdda.europa.eu/publications/emcdda-papers
(2) Public austerity: a slowdown or reduction of budget deficits, which is not caused by a reduction in the 
demand for the underlying public service, but implemented by governments on a discretionary basis.
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New EMCDDA Paper explores the impact of the 
recession on the financing of drug policy in Europe.
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Reitox Academy kicks off 
scientific cooperation with Israel
‘Estimating public expenditure in the field of drugs in Israel’ 
was the focus of a Reitox Academy organised by the EMCDDA 
and the Israel Anti-Drug Authority (IADA) from 30 September to 
1 October in Tel Aviv. 
The event marked the start of scientific cooperation between 
the two organisations, following a Memorandum of 
Understanding (MoU) signed in February 2014 (1). It was also 
the first activity organised in Israel in the framework of the 
EMCDDA’s European Neighbourhood Policy (ENP) technical 
cooperation project, funded by the European Commission (2). 
The academy was organised to support a study being launched 
in Israel by IADA on ‘Estimating drug-related public expenditure, 
social costs and cost-utility’. This project, planned to start in 
2015 and last for 30-months, will run in two stages: estimating 
drug-related public expenditure and social costs in Israel 
(Stage 1); and Performing a cost-utility analysis (Stage 2).
The event gathered 33 Israeli experts, representing the areas of 
health, education, police, public security, justice, prisons, social 
welfare and scientific research. Also present were experts from 
France, Italy, Croatia and the EMCDDA. The academy provided 
a platform for sharing experience on estimating the different 
components of drug-related expenditure and discussing the 
main strengths and limitations of the methods used.
 Cláudia Costa Storti, Yossi Harel-Fisch and Ilze Jekabsone 
(1) See www.emcdda.europa.eu/news/2014/fs2. For more on the IADA, see 
www.antidrugs.org.il
(2) See http://ec.europa.eu/world/enp/index_ en.htm. See also p. 6.
Strengthening ties with global 
partners
Three experts from the Department of Mental Health and 
Substance Abuse of the World Health Organization (WHO) in 
Geneva visited the EMCDDA on 13 October where they met 
with the EMCDDA’s senior scientific staff. The aim of this 
meeting was to review ongoing collaboration between the 
organisations and to plan future activities in the area of 
substance use and related disorders. The WHO is one of the 
EMCDDA’s most important partners, with working relations now 
spanning almost two decades (1). 
In recent years, collaboration between the two bodies has 
focused on quality standards in interventions and the 
monitoring of treatment systems. In 2014 alone, the EMCDDA 
has contributed to the development of the WHO’s Guidelines on 
the management of suspected opioid overdose and Guidelines 
for the identification and management of substance use 
disorders in pregnancy. Ties between the two agencies were 
also strengthened when the EMCDDA participated this year in 
the WHO Expert Committee on Drug Dependence.
The Lisbon meeting coincided with the WHO’s preparations for 
the UN General Assembly Special Session (UNGASS) on drugs 
in 2016 and with ongoing international drug policy debates on 
cannabis and new psychoactive substances. It helped identify 
areas for common work in future, such as: harmonising 
indicators, data-collection instruments and information 
systems; disseminating evidence-based interventions and 
cooperating with non-EU countries.
 Klaudia Palczak 
(1) www.emcdda.europa.eu/about/partners/who
INTERNATIONAL PARTNERS
DRUGS-LEX
Legal issues around the provision of naloxone
Research in Europe is today confirming that the opioid 
antagonist naloxone can be used successfully by bystanders 
to reverse opioid overdoses, if administered in due time. 
Given that the majority of drug-induced deaths across Europe 
are related to opioid use, some countries are now examining 
how to scale up the provision of naloxone to at-risk users, 
their families and peer groups, so that the substance is 
available where emergencies are likely to occur.
This intention, however, has met with some legal obstacles. 
These, and possible solutions to them, were discussed at the 
EMCDDA’s Legal and policy correspondents’ network meeting 
in June and at its naloxone event in October (see p. 2). 
The initial findings from these meetings fall into three groups: 
n  Availability — in most European countries, naloxone is 
licensed as an injectable prescription-only medicine; 
legally, it is not easy to prescribe a medicine to one person 
when it will be used for another;
n  Prescribing and use — in many countries, use of naloxone 
was either legally or in practice limited to hospital or 
emergency personnel, although several countries now 
allow general practitioners to prescribe or use it; 
n  Penalties for unauthorised possession or use — in theory 
this may be an administrative or criminal offence in 
several countries. However, more serious fears of 
naloxone possession being charged as ‘facilitating/
encouraging illegal drug use’ seem to be unfounded. 
These first results suggest that legal barriers arise, not so 
much from the nature of the substance itself but from its 
route of administration: it is rare to permit one untrained 
person to inject another. These issues are being addressed by 
training peers in injection techniques (Denmark, Estonia, 
Scotland) and by developing nasal spray applicators 
(Norway), based on promising results in projects in the US. 
 Brendan Hughes and Dagmar Hedrich 
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NEW PSYCHOACTIVE SUBSTANCESSPOTLIGHT
EMCDDA hosts 
third Reitox week
Candidate, potential candidate and 
neighbouring countries of the EU, 
preparing to collaborate with the 
EMCDDA, participated in the third 
‘Reitox week’ held in Lisbon from 
25–28 November. This annual event 
brought together representatives of 
over 40 nations including: the current 
30 members of the network, Russia 
and a number of beneficiaries of the 
European Instrument for Pre-Accession 
Assistance (IPA) and the European 
Neighbourhood Policy Instrument (ENPI).
This year, the event observed the 
official closure of a technical 
cooperation project with Albania, 
Bosnia and Herzegovina, Montenegro, 
Kosovo*, Serbia, the former Yugoslav 
Republic of Macedonia and Turkey. 
The national correspondents from 
these countries presented the results 
of this three-year project, initiated in 
January 2012 (IPA 4). The event also 
gave the EMCDDA the chance to 
present the first regional report on 
drug use in the Western Balkans.
The 2014 Reitox week was also special 
in that it included a full-day session on 
cannabis legislation and policy. Here, 
the participants heard experts from 
the US, Latin America and Europe 
share their knowledge on 
developments in this area and the 
knock-on challenges for drug 
monitoring. The meeting of the 
extended network was followed by the 
regular meeting of the 30 Reitox 
members (26–28 November) which 
examined content-related issues such 
as a new reporting system and the 
agency’s work programme 2015.
 Cécile Martel 
* This designation is without prejudice to 
positions on status, and is in line with UNSCR 
1244 and the ICJ Opinion on the Kosovo 
Declaration of Independence.
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Four new drugs to be placed under control
On 25 September, EU Ministers adopted 
a European Commission proposal to 
control four new psychoactive 
substances (NPS) currently raising 
health concerns in Europe (1). With the 
decision, the substances 25I-NBOMe, 
AH-7921, MDPV and methoxetamine will 
be subject to control measures and 
criminal penalties throughout the EU.
In April 2014, the extended EMCDDA 
Scientific Committee examined the four 
drugs and submitted its risk-assessment 
reports to the European Commission and 
the Council of the EU. On the basis of 
these, the Commission recommended to 
the Council on 16 June that the drugs be 
submitted to control measures, given 
that severe toxicity has been associated 
with their use (2).
The final decision entered into force the 
day after its publication in the Official 
Journal of the European Union on 
1 October 2014. Member States now 
have one year to take the necessary 
measures to subject those substances to 
control measures and criminal penalties, 
as provided for under their legislation 
(complying with their obligations under 
the 1971 United Nations Convention on 
Psychotropic Substances).
Two other NPS raising health concerns in 
Europe were risk-assessed by the 
EMCDDA extended Scientific Committee 
on 16 September (3). The first of these is 
4,4′-DMAR, a derivative of aminorex with 
psychostimulant properties, which has 
been available on the drug market since 
at least December 2012. The second is 
MT-45, a synthetic opioid investigated in 
the 1970s for its analgesic properties 
and detected for the first time on the 
European drug market in October 2013. 
Respectively, a total of 31 and 28 deaths 
were associated to these drugs and, in all 
cases, the presence of the substance in 
biological samples was analytically 
confirmed.
 Ana Gallegos 
(1) For more, see www.emcdda.europa.eu/
news/2014/four-new-drugs-to-be-placed-under-
control and www.emcdda.europa.eu/news/2014/1
(2) http://europa.eu/rapid/midday-
express-16-06-2014.htm
(3) www.emcdda.europa.eu/publications/
risk-assessments. See also p. 7.
Technical cooperation project: ENP countries
In recent months, the EMCDDA has 
undertaken a raft of activities with EU 
neighbouring countries, under a two-year 
technical cooperation project in the 
framework of the European 
Neighbourhood Policy Instrument 
(ENPI) (1). This European Commission-
funded project, which will run until 
December 2015, is designed to boost the 
capacity of ENP partner countries to 
react to fresh challenges posed by the 
drug phenomenon. 
In July, the agency contributed to the 
drafting of the national report on the 
drug situation in Morocco and will 
support other partner countries in this 
exercise in the coming months. 
In October, cooperation with Moldova 
and Georgia was enhanced through 
official visits to the countries. Several 
training activities have also been 
organised with partners: ‘Contemporary 
approaches in drug monitoring’, with the 
Charles University in Prague 
(September); and ‘The European Union, 
the EU drugs policy and relations with 
the European Neighbourhood Policy 
partner countries’, with the College of 
Europe in Brussels (October). A national 
Reitox Academy took place in Tel Aviv in 
September (see p. 5). 
Looking to 2015, the EMCDDA will 
organise, under this project, an ENP 
regional activity on forensic laboratories 
and new drugs. It will also strive to 
improve existing data-collection systems 
and/or co-finance surveys in the partner 
countries (e.g. ESPAD school survey). 
 Cécile Martel 
(1) See Drugnet Europe 85, p. 6.
REITOX
 Severe toxicity has been  
 associated with the use of  
 these substances 
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PRODUCTS AND SERVICES EVENTS
Talk HIV. Test HIV
In the lead-up to World AIDS Day on 
1 December, a second European HIV 
testing week was organised from 
21–28 November. This initiative, 
coordinated by HIV in Europe, offers an 
opportunity for partners across Europe 
to unite for one week to help more 
people become aware of their HIV 
status. HIV in Europe is an initiative 
directed by an independent group of 
experts with representation from civil 
society, policymakers, health 
professionals and European public 
health institutions.
For more, see http://www.hivtestingweek.eu/
home and http://hiveurope.eu/
Hepatitis C Initiative
Today the hepatitis C virus (HCV) 
affects an estimated 9 million 
European citizens. People who inject 
drugs (PWID), or who injected in the 
past, are the largest group, with 
estimated prevalence rates in some 
European countries of up to 90 %. 
Without proper treatment, HCV can be 
a serious and even deadly disease. 
The Hepatitis C Initiative, an EU-funded 
project bringing together over 30 
organisations working on infectious 
diseases, aims to help improve 
knowledge regarding hepatitis C 
policies and practice. Under this 
initiative, the First European 
conference on hepatitis C was held 
from 23–24 October in Berlin (the 
EMCDDA sat on the steering 
committee). The conference 
culminated in the presentation of the 
‘Berlin Declaration’, a call to national 
and European policymakers to ensure 
better access and quality of hepatitis 
treatment for the most marginalised 
groups and individuals.
http://www.hepatitis-c-initiative.eu/  
http://conference.hepatitis-c-initiative.eu/index.
html
Pregnancy and opioid use: 
strategies for treatment
Illicit opioid consumption during pregnancy brings with it 
the risk of an increase in obstetric complications for the 
mother as well as a range of potential dangers for the child, 
both before and immediately after birth. The primary goal 
when treating opioid dependence in pregnant women is to 
stabilise the patient. Psychosocially assisted opioid 
substitution treatment is the preferred first-line therapy for 
this group and several combinations of substitution 
medicines and psychosocial approaches are available. This latest EMCDDA Paper 
reviews methadone, buprenorphine and slow-release oral morphine, used in a range 
of combinations with cognitive behaviour approaches and contingency management, 
to identify the strengths of each medicine and method. 
Available in English at: www.emcdda.europa.eu/publications/emcdda-papers
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Joint Reports: 4,4′-
DMAR and MT-45
Once a new psychoactive substance is 
detected on the European drug market, 
Member States ensure that information on the 
manufacture, traffic, use, health effects and 
toxicity of the drug is transmitted to the 
EMCDDA and Europol. If the two agencies 
consider that information collected on a new 
substance merits active follow-up, further 
information is collected and presented in a 
Joint Report to the Council of the EU, the 
European Commission and the European 
Medicines Agency (EMA), on the basis of which 
a decision may be taken on whether or not to 
launch a formal risk-assessment procedure. 
In line with this process, and following examination of the information in February and 
April respectively, two Joint Reports were prepared on the substances 4,4′-DMAR and 
MT-45 (see p. 6). The reports paved the way for formal risk assessments in September 
2014. The reports are now available on the EMCDDA website, while the risk 
assessment reports will be available in the coming weeks.
Available in English at: www.emcdda.europa.eu/publications/joint-reports
Technical report: GPS
Computer-assisted and online data collection in general population surveys is the title 
of a new EMCDDA Technical report published in October. The aim of the report is to 
collect information from a literature review on computer-assisted interviewing and 
online data collection in general population surveys (GPS). It evaluates the pros and 
cons of both approaches in terms of research processes and outcomes. It also 
provides an overview of representative studies on drug use conducted in the 
30 EMCDDA countries that used one of these methods.
Available in English at: www.emcdda.europa.eu/publications/technical-reports/online-data-collection-gps
Subscribe to our ‘Just published’ online newsletter for news on our latest and upcoming products 
www.emcdda.europa.eu/publications/subscribe
CALENDAR 2014 EMCDDA Scientific Committee 
endorses 2015 work programme
The EMCDDA Scientific Committee met in Lisbon from 17–18 
September, adopting a formal opinion on the agency’s 2015 
work programme and holding preliminary discussions on the 
2016–18 EMCDDA strategy (1). The scientific evaluation of 
policies and interventions and the process for reviewing 
EMCDDA publications were also discussed, as were improved 
procedures for future rounds of the EMCDDA scientific paper 
award. Recent developments in the risk assessment of new 
psychoactive substances were also reviewed. 
The EU action plan on drugs (2013–16) calls on the EMCDDA 
Scientific Committee to contribute to the Annual Dialogue on 
Research (ADR) of the Horizontal Working Party on Drugs/HDG 
(Council of the EU). In line with Action 46 of the action plan, this 
advisory input involves proposing research priorities (within 
areas covered by the expertise of the Committee), as well as 
suggesting ways to promote synergies and complementarity 
and prevent overlaps in research funding. During their meeting, 
the Committee adopted its formal contribution to this year’s 
ADR, which followed on 5 November in Brussels (2).
 Maria Moreira 
(1) See Drugnet Europe 87, p. 5.
(2) For more, see www.emcdda.europa.eu/about/sc
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EMCDDA meetings
29 October: Launch of the Romanian national report 
on drugs, Bucharest.
30–31 October: Trendspotter meeting: ‘The internet and 
drug markets’, Lisbon.
4–5 November: 2nd annual meeting of the EMCDDA 
reference group on drug supply 
indicators, Lisbon.
12 November: National launch of the European Drug 
Report 2014, Vilnius.
25–28 
November:
3rd extended Reitox week and 51st 
Heads of Reitox focal point meeting, 
Lisbon.
25 November: EMCDDA Scientific paper award 2014 
ceremony, Lisbon.
4 December: EMCDDA Budget and Executive 
Committee meetings, Lisbon.
4–5 December: 50th EMCDDA Management Board 
meeting, Lisbon.
External meetings
5–7 November: ESCAIDE 2014 conference, Stockholm.
12–13 
November:
2nd international symposium on drugs 
and driving, New Zealand drug 
foundation, Wellington 
(http://drugdriving.org.nz).
18 November: G7 expert meeting on new 
psychoactive substances (NPS), 
Federal Ministry of the Interior, Berlin.
19–20 
November:
16th Ministerial conference of the 
Pompidou Group, Strasbourg.
EU meetings
3 November Heads of EU Justice and Home Affairs 
agencies, Valletta.
4–5 November: Horizontal working party on drugs, 
EU–US meeting, Dublin Group, 
Brussels.
13–14 
November:
National drug coordinators’ meeting, 
Rome.
10–11 
December:
Horizontal working party on drugs and 
EU–Brazil meeting, Brussels.
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H. J., Ecker, G. F., Bochkov, V., Galli, A., Boehm, S., Sitte, H. H. 
(2013), ‘Amphetamine actions at the serotonin transporter rely 
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Proceedings of the National Academy of Sciences of the 
United States of America, 110, 28, p. 11642–47.
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with attention deficit hyperactivity disorder: a 4-year follow-up 
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